Health Canada has released results from its collaboration known as Project Orbis, linking international agencies to speed-up patient access.
In its press release, Health Canada describes two products to go through Project Orbis in 2019: Lenvima and Keytruda as a combination treatment, and Calquence.
Project Orbis enabled simultaneous review by Health Canada, the US Food and Drugs Administration (FDA) and the Australian Therapeutic Goods Administration (TGA). Only cancer drugs are entered into Orbis.
Health Canada says:
“This collaborative effort with the FDA and TGA allowed for simultaneous review and therefore earlier approval of this medication for Canadians with cancer.”